Skip to Content
Silicon Valley

Facebook had plans to break into medical data sharing

But its project to hoover up patient records from hospitals is currently on hiatus, for what should be obvious reasons.

The news: CNBC reports that Facebook “asked several major US hospitals to share anonymized data about their patients … for a proposed research project.”

Details: The idea was to give medical researchers more information on patients by tying user data to medical records while obscuring private details from data handlers using a cryptographic technique known as hashing.

What we don't know: Rather a lot. Would patients get the choice to opt in? And how would it comply with the Health Insurance Portability and Accountability Act, which outlines data privacy rules for safeguarding medical information?

But: Facebook says the work has “not progressed past ... planning.” It also says that it has shelved the project for now, so it can do “important work, including ... a better job of protecting people's data."

Why it matters: You may have heard—Facebook is embroiled in a huge data scandal. This news will only serve to increase fears about the firm’s growing access to personal information.

Keep Reading

Most Popular

open sourcing language models concept
open sourcing language models concept

Meta has built a massive new language AI—and it’s giving it away for free

Facebook’s parent company is inviting researchers to pore over and pick apart the flaws in its version of GPT-3

transplant surgery
transplant surgery

The gene-edited pig heart given to a dying patient was infected with a pig virus

The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.

Muhammad bin Salman funds anti-aging research
Muhammad bin Salman funds anti-aging research

Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging

The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.

Yann LeCun
Yann LeCun

Yann LeCun has a bold new vision for the future of AI

One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at with a list of newsletters you’d like to receive.